← All trials
NCT06747507
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2025
- Primary completion
- Aug 31, 2026
- Completion date
- Feb 28, 2027
- First posted
- Dec 24, 2024
- Last posted
- Dec 24, 2024
- Enrollment
- 392
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of NairobiLead sponsor
- University of LondonCollaborator
- SolidarMedCollaborator
- University of NairobiOfficial
- Government of MozambiqueCollaborator
- University of NairobiSponsor investigator
- Muhimbili UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.